CEL-SCI Corporation (NYSE American: CVM) announced the closing of its best-efforts public offering of 6 million shares of common stock at $1.20 per share, generating gross proceeds of approximately $7.2 million before fees and expenses. The company stated that net proceeds will be used to support the continued development of Multikine, its investigational immunotherapy for head and neck cancer, as well as for general corporate purposes and working capital.
Multikine (Leukocyte Interleukin, Injection) is designed to be administered after diagnosis but before surgery, radiotherapy, and chemotherapy, aiming to boost the patient's immune system while it is still relatively intact. According to CEL-SCI, this approach is thought to enable a more effective immune attack on the tumor. The therapy has been dosed in over 740 patients and has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck.
The successful closing of this offering provides CEL-SCI with additional capital to advance its clinical programs. The company believes that boosting a patient's immune system before standard treatments damage it should provide the greatest possible impact on survival. With the FDA's Orphan Drug designation, Multikine has the potential to address an unmet medical need in head and neck cancer, a disease that affects thousands of patients annually.
For investors and the biotechnology industry, this funding round signals continued confidence in CEL-SCI's approach and its ability to bring Multikine through the development pipeline. The proceeds will help the company navigate the costly clinical trial process and potentially bring a novel therapy to market. More information about the offering and the company can be found in the full press release at https://ibn.fm/T5Ng2.
CEL-SCI operates in Vienna, Virginia, and near/in Baltimore, Maryland. The company's commitment to developing Multikine reflects a broader trend in oncology toward immunotherapies that harness the body's own immune system to fight cancer. If successful, Multikine could become a standard part of neoadjuvant therapy for head and neck cancer, potentially improving outcomes for patients. For further details about the company and its pipeline, visit https://cel-sci.com/.
